MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
TherapeuticsMD Accounts Receivables 2011-2026 | TXMD
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables TherapeuticsMD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 32.4 M | 24.4 M | 11.1 M | 4.33 M | 4.5 M | 3.05 M | 2.15 M | 1.69 M | 607 K | 26.7 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32.4 M | 26.7 K | 8.42 M |
Quarterly Accounts Receivables TherapeuticsMD
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | 32.2 M | 45.8 M | 35.4 M | 36.2 M | 37.4 M | 33.5 M | 33.7 M | 32.4 M | 32.4 M | 32.4 M | 32.4 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 4.33 M | 4.33 M | 4.33 M | 4.33 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 3.05 M | 3.05 M | 3.05 M | 3.05 M | 2.15 M | 2.15 M | 2.15 M | 2.15 M | 1.69 M | 1.69 M | 1.69 M | 1.69 M | 714 K | 607 K | 607 K | 607 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 45.8 M | 26.7 K | 12.6 M |
Accounts Receivables of other stocks in the Drug manufacturers industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
34.5 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.05 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
47.5 M | $ 1.19 | 0.85 % | $ 128 M |  Canada |
 |
Aerie Pharmaceuticals
AERI
|
68.8 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
160 K | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
3.39 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
921 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
1.26 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
72.4 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
387 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
673 K | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
191 M | $ 13.9 | 5.7 % | $ 712 M | USA |
 |
Pacira BioSciences
PCRX
|
113 M | $ 26.0 | 2.73 % | $ 1.2 B | USA |
 |
Athenex
ATNX
|
27.9 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
34.1 M | $ 21.5 | - | $ 2.05 B |  France |
 |
Sonoma Pharmaceuticals
SNOA
|
2.23 M | $ 3.74 | -1.58 % | $ 4.64 M | USA |
 |
Evolus
EOLS
|
47.7 M | $ 5.66 | -4.23 % | $ 351 M | USA |
 |
Harrow Health
HROW
|
15.1 M | $ 51.0 | -4.67 % | $ 1.66 B | USA |
 |
China Pharma Holdings
CPHI
|
232 K | $ 1.35 | 5.88 % | $ 23.6 M |  China |
 |
Jupiter Wellness
JUPW
|
512 K | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
2 B | $ 7.9 | 3.47 % | $ 2.88 B | Canada |
 |
Veru
VERU
|
3.96 M | $ 2.37 | 1.72 % | $ 320 M | USA |
 |
Lannett Company
LCI
|
56.2 M | - | 1.15 % | $ 7.11 M | USA |
 |
cbdMD
YCBD
|
622 K | $ 1.1 | -4.35 % | $ 4.74 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
11.7 M | $ 5.19 | 9.96 % | $ 73 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
65.4 K | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
110 M | $ 4.3 | -1.38 % | $ 566 M | USA |
 |
PetIQ
PETQ
|
143 M | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
16.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Perrigo Company plc
PRGO
|
642 M | $ 14.59 | -1.19 % | $ 2 B | USA |
 |
ProPhase Labs
PRPH
|
37.1 M | - | - | $ 5.07 M | USA |
 |
Rockwell Medical
RMTI
|
10.9 M | $ 0.95 | 2.78 % | $ 22.2 M | USA |
 |
Radius Health
RDUS
|
20.3 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
512 K | $ 4.32 | 5.88 % | $ 130 M | USA |
 |
OptiNose
OPTN
|
19.9 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
47.7 M | $ 9.43 | -1.05 % | $ 670 M | USA |
 |
PLx Pharma
PLXP
|
634 K | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
2.1 M | $ 0.64 | -0.05 % | $ 30.6 M | USA |
 |
Tilray
TLRY
|
86.2 M | $ 8.99 | -2.92 % | $ 5.56 B | Canada |
 |
Viatris
VTRS
|
3.24 B | $ 12.46 | 0.48 % | $ 15.1 B | USA |
 |
Zomedica Corp.
ZOM
|
1.2 M | - | -0.21 % | $ 98 M | USA |